Global wellposed problem for the 3-D incompressible anisotropic Navier-Stokes equations

In this paper, we consider a global wellposed problem for the 3-D incompressible anisotropic Navier-Stokes equations (\textit{ANS}). In order to do so, we first introduce the scaling invariant Besov-Sobolev type spaces, $B^{-1+\frac{2}{p},{1/2}}_{p}$ and $B^{-1+\frac{2}{p},{1/2}}_{p}(T)$, $p\geq2$. Then, we prove the global wellposedness for (\textit{ANS}) provided the initial data are sufficient small compared to the horizontal viscosity in some suitable sense, which is stronger than $B^{-1+\frac{2}{p},{1/2}}_{p}$ norm. In particular, our results imply the global wellposedness of (\textit{ANS}) with high oscillatory initial data.Comment: 39 page

On 2D Viscoelasticity with Small Strain

An exact two-dimensional rotation-strain model describing the motion of Hookean incompressible viscoelastic materials is constructed by the polar decomposition of the deformation tensor. The global existence of classical solutions is proved under the smallness assumptions only on the size of initial strain tensor. The proof of global existence utilizes the weak dissipative mechanism of motion, which is revealed by passing the partial dissipation to the whole system.Comment: Different contributions of strain and rotation of the deformation are studied for viscoelastic fluids of Oldroyd-B type in 2

Energy Dissipation and Regularity for a Coupled Navier-Stokes and Q-Tensor System

We study a complex non-newtonian fluid that models the flow of nematic liquid crystals. The fluid is described by a system that couples a forced Navier-Stokes system with a parabolic-type system. We prove the existence of global weak solutions in dimensions two and three. We show the existence of a Lyapunov functional for the smooth solutions of the coupled system and use the cancellations that allow its existence to prove higher global regularity, in dimension two. We also show the weak-strong uniqueness in dimension two

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362